Company intelligence / Profile preview

Exsymol

Monaco, Monaco, Monaco

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Exsymol’s cosmetic actives have demonstrated efficacy in anti-aging, skin hydration, and anti-glycation, supported by both clinical and in vitro data; their latest innovation, ADENOSILANE, won the BSB Innovation Award 2022 for anti-aging and pore tightening obtained via biotechnological fermentation[5].

Therapeutic areas: Metabolic DisordersDermatology
Modalities: Small moleculePeptidesOrganic silicon derivativesBotanical extractsBiomolecule derivatives
Industry: Non-Drug Biotech

Partnerships

35+ international distributorsPartnerships with major cosmetic brands (not public, but referenced as "the biggest cosmetic brands")

Beyond the preview

Go deeper on Exsymol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exsymol.

Explore the full profile